Bone Biologics (NASDAQ:BBLG) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Bone Biologics (NASDAQ:BBLG) from a sell rating to a hold rating in a research report report published on Sunday morning.

Bone Biologics Stock Up 15.3%

Shares of BBLG stock opened at $2.79 on Friday. The stock has a fifty day moving average of $2.36 and a 200 day moving average of $3.69. Bone Biologics has a 52 week low of $1.95 and a 52 week high of $13.80.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.75). Equities analysts anticipate that Bone Biologics will post -5 EPS for the current year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.